Optimizing Quadruple Therapy in Heart Failure
Drs James Januzzi, Javed Butler, Robert J. Mentz, and Muthiah Vaduganathan share approaches to sequencing quadruple therapy in heart failure to the individual patient, as well as optimizing therapy early in the hospitalization stage.
SGLT-2 Inhibitors in Heart Failure
Javed Butler, MD, MPH, MBA, discussesSGLT-2 inhibitors and their use in heart failure.
Foundations of Quadruple Therapy in Heart Failure
Experts in cardiology highlight the four pillars of guideline directed therapies in heart failure.
A Patient-Centered Approach to Heart Failure
Robert J. Mentz, MD, and James Januzzi, MD, discuss the key takeaways from updated heart failure guidelines, highlighting heart failure stages A and B.
Diagnostic Algorithm for Heart Failure from Recent Guidelines
Muthiah Vaduganathan, MD, MPH, and Javed Butler, MD, MPH, MBA, share approaches to treating patients with heart failure, focusing on patient education as well as social determinants of health.
Universal Classification of Heart Failure
Experts in cardiology review the classification of heart failure using left ventricle ejection fraction (EF).
Impact of Heart Failure on Survival
Muthiah Vaduganathan, MD, MPH, comments on the impact of recurrent rehospitalizations for heart failure on survival.
The Prevalence of Heart Failure and Challenges in its Management
Javed Butler, MD, MPH, MBA, and Robert J. Mentz, MD, review the current prevalence of heart failure in the US and Europe, as well as the clinical and economic challenges that arise with increasing prevalence.
Patient Education of HCM
Expert cardiologists share strategies for educating patients on the treatment and management of hypertrophic cardiomyopathy.
Future Directions for oHCM Treatment
Drs Steve R. Ommen, Martin S. Maron, Javed Butler, and James Januzzi provide insight on the evolving treatment landscape for obstructive hypertrophic cardiomyopathy.
VALOR-HCM Study in oHCM
A panel of experts in cardiovascular medicine review the use of mavacamten as seen in the VALOR-HCM study for patients with symptomatic oHCM who are eligible for septal reduction therapy.
Long-Term Data of Mavacamten Use in oHCM
Martin S. Maron, MD, examines long-term data with mavacamten for oHCM treatment that was presented at ACC 2022.
Health Status With Different HCM Treatments
Cardiac specialists discuss improvement in health status with different treatments for hypertrophic cardiomyopathy.
EXPLORER-HCM Trial in oHCM
John A. Spertus, MD, MPH, and Martin S. Maron, MD comment on the role of mavacamten in oHCM as seen in the EXPLORER-HCM trial.
Emerging Therapies for oHCM
Steve R. Ommen, MD, discusses the use of novel agents in the pipeline for the treatment of obstructive hypertrophic cardiomyopathy (oHCM).
Approaching Treatment Selection for Hypertrophic Cardiomyopathy
Steve R. Ommen, MD, leads a discussion on factors to consider when choosing treatment for hypertrophic cardiomyopathy (HCM).
Invasive Treatments and Challenges with HCM Treatments
Experts in cardiology review invasive treatments, challenges with HCM treatments, and how to optimize treatment for patients.
Treatment Approaches for HCM
Drs Javed Butler, Martin S. Maron, Steve R. Ommen, and James Januzzi provide insight on approaching treatment of HCM with pharmacologic and nonpharmacologic interventions.
AHA/ACC HCM Guidelines and Patient Identification and Management
Steve R. Ommen, MD; and Martin S. Maron, MD, review the role of AHA/ACC guidelines, imaging techniques, and circulating biomarkers in approaching the diagnosis and treatment of hypertrophic cardiomyopathy.
The Effect of Obstructive Hypertrophic Cardiomyopathy on Health Status
John A. Spertus, MD, MPH, comments on the effect of oHCM on health status and quality of life for patients.
Symptoms of Hypertrophic Cardiomyopathy
Drs Steve R. Ommen, Martin S. Maron, John A. Spertus, Javed Butler, and James Januzzi provide insight on the presentation of nonobstructive and obstructive hypertrophic cardiomyopathy.
Role of Genetic Mutations in HCM Pathophysiology
Steve R. Ommen, MD, leads a review of common mutations seen in hypertrophic cardiomyopathy and the role of biomarkers and genetic testing in HCM.
Overview of Hypertrophic Cardiomyopathy
Martin S. Maron, MD, discusses the incidence and prevalence of hypertrophic cardiomyopathy and age of disease expression.
2 Clarke Drive Cranbury, NJ 08512